labcorp america lh
refin expect note sever bright spot lh
core lcd segment includ encourag organ laboratori volum
higher expect rev/accn revis
estim better reflect contract shift time recent
food solut divestitur increment pressur lcd growth
profit come year consequ lower ep
aforement headwind lcd tp
move reduc view importantli continu
view longer term growth driver intact lh better posit
achiev profit margin expans beyond risk includ
tighten biotech fund demand shift potenti integr
headwind government reimburs chang hospit lab competit
reiter outperform lt driver intact remind may lh
disclos renew current exclus contract
slate expir howev
continu particip nation provid laboratori servic
patient non-exclus basi dynam view broadli
exclus relationship well non-exclus term
previous exclus aetna contract repres estim
lh lcd revenu total sale lh provid detail
financi impact new contract lh lost half
associ revenu overnight rather aggress assumpt
would repres estim ep headwind
sever variabl consid importantli potenti offset henc
take conserv approach latest estim revis
continu view multipl avenu growth across lh
diversifi platform despit aforement headwind core lcd
recent food solut divestitur conjunct strong cf gener
offer capit deploy flexibl particularli relev given role
lead consolid smaller lab oper post-pama world
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
labcorp provid diagnost test inform servic
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
labcorp america lh
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
labcorp america lh
cro growth engin lh entranc cro market revenu
covanc acquisit underscor diversif strategi unteth broader lab
trend expect covanc leverag bolster abil fsp/apac well
proprietari data asset expedit patient recruit addit chiltern
associ launchpad cost save also enhanc profit profil note
sequenti lower ttm net-btb vs metric still came
threshold perceiv healthi build momentum biotech fund
recent announc strateg partnership also support favor bia also
highlight impli valuat disconnect cro segment base sotp
analysi ascrib ev/ebitda multipl line quest diagnost
core lcd impli multipl cro discount
detail recent contract dynam
remind may lh disclos renew current exclus
contract slate expir howev
continu particip nation provid laboratori servic patient
non-exclus basi dynam view broadli anticip unsurprisingli
simultan announc new relationship
non-exclus basi well loss exclus aetna remind
revenu current repres estim lh lcd revenu
total compani sale announc come year investor concern
implic intern competit loss exclus serv
overhang lh share addit pama lh provid
detail financi impact loss exclus analysi purpos lh lost
half associ revenu overnight rather aggress assumpt would
repres ep headwind sever variabl consid
importantli potenti offset henc take conserv approach
assumpt latest ep estim revis
overal new contract term weigh profit cours
could spur increment share gain lh well smaller region lab
previous benefit exclus natur contract continu view
multipl avenu growth lh includ role lead consolid smaller
lab oper post-pama world aforement organ market share gain
region lab notabl strengthen perform covanc
view impli valuat disconnect reiter outperform
labcorp america lh
labcorp america
dollar million decemb fye
sale
sale
corpor
labcorp america lh
compani mention price
labcorp america lh outperform tp
